Lantheus Holdings, Inc. 10-K

Item 2. Properties The following table summarizes information regarding our significant leased and owned properties, as of December 31, 2020: Location Purpose Segment Square Footage Ownership Lease Term End U.S. North Billerica, Massachusetts Corporate Headquarters, Manufacturing, Laboratory, Mixed Use and Other Office Space U.S. Segment 431,000 Owned N/A New York, New York Progenics Headquarters, Office Space U.S. Segment 26,000 Leased September 2030 Somerset, New Jersey Manufacturing, Mixed Use and Office Space U.S. Segment 11,400 Leased November 2028 Canada Quebec Mixed Use and Office Space International Segment 1,106 Leased April 2021 Quebec Distribution Center and Office Space International Segment 1,433 Leased May 2022 Puerto Rico San Juan Manufacturing, Laboratory, Mixed Use and Office Space International Segment 9,550 Leased October 2024 Sweden Lund Office Space International Segment 4,000 Leased December 2021 We believe all of these facilities are well-maintained and suitable for the office, radiopharmacy, manufacturing or warehouse operations conducted in them and provide adequate capacity for current and foreseeable future needs. On November 30, 2020, we entered into an agreement to sell our Puerto Rico radiopharmacy and PET manufacturing facility (“PMF”) to PharmaLogic, one of our existing radiopharmacy customers. The transaction closed on January 29, 2021. Item 3. Legal Proceedings Information with respect to certain legal proceedings is included in Note 19, “Commitments and Contingencies”, to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, and is incorporated herein by reference. Item 4. Mine Safety Disclosures Not applicable 57 Table of Contents PART II